<DOC>
	<DOCNO>NCT00949546</DOCNO>
	<brief_summary>Therapy etanercept , TNF inhibitor reverse inflammation , symptom quality life allow heal HS .</brief_summary>
	<brief_title>Treatment Hidradenitis Suppurativa Using Etanercept</brief_title>
	<detailed_description />
	<mesh_term>Hidradenitis</mesh_term>
	<mesh_term>Hidradenitis Suppurativa</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Chronic HS &gt; 6months defined tender and/or painful , red nodule and/or plaque ( confluent nodule ) without scar , foul odor , drain sinus clinically HS Localizes skin fold include axillx , breast , abdomen groin active disease Negative pregnancy test within 7 day first dose study drug Sexually active subject childbearing potential must agree use medically acceptable form contraception screen throughout study Concurrent active infection include tuberculosis Concurrent therapy therapy 30 day prior systemic corticosteroid , systemic immunosuppressant , systemic retinoids antTNF agent Severe comorbidities ( diabetes mellitus require insulin , Q F severity , MI , unstable angina eectoris , uncontrolled hypertension , oxygendependent severe pulmonary disease , history cancer *thin 5_ year except cutaneous basal cell squamous cell carcinoma situ cervical carcinoma , history TB TB exposure , chronic hepatitis B C , SLE , history multiple sclerosis , transverse myelitis , optic neuritis epilepsy Currently enrol enrol within 90 day prior trial treatment HS Known HIV positive Contraindication etanercept define package insert</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
</DOC>